Skip to main content
Premium Trial:

Request an Annual Quote

Cell Microsystems Acquires Fluxion Biosciences; Announces Series B Financing

NEW YORK – Cell biology technology firm Cell Microsystems said on Wednesday that it has acquired Fluxion Biosciences, an Oakland, California-based company that produces automated patch clamp technology and cell-based assay tools.

The acquisition was supported by a concurrent Series B financing led by Telegraph Hill Partners, the Durham, North Carolina-based Cell Microsystems said in a statement, but the company did not disclose the exact amount raised by the funding round. Other financial details of the deal were not disclosed.

Cell Microsystems said the acquisition of Fluxion and its IonFlux, BioFlux, and IsoFlux products "adds to its portfolio to form a suite of innovative cell analysis solutions."

Jeff Jensen, formerly CEO of Fluxion, and his team will join Cell Microsystems after the acquisition.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.